Innovative Arzneimittel sofort verfügbar machen, nationale Zuständigkeit sichern und lernende Preisbildung weiterentwickeln

This procedure concerns proposals to speed up the availability of innovative medicines in Germany. It aims to balance patient access with national regulatory responsibilities and adapt pricing models to encourage learning and development in the pharmaceutical sector. The proposals could affect patients seeking new treatments, pharmaceutical companies, and the national health system. It seeks to ensure Germany can adapt pricing based on a medicine's learning curve and long-term value.